nach oben

Erschienen in:

01.04.2013

Pancreatic neuroendocrine neoplasms: diagnosis and management

verfasst von: Aparna Balachandran, Eric P. Tamm, Priya R. Bhosale, Madhavi Patnana, Raghu Vikram, Jason B. Fleming, Matthew H. Katz, Chuslip Charnsangavej

Erschienen in: Abdominal Radiology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic neuroendocrine neoplasms are uncommon but rising in incidence. There have been recent changes in the WHO nomenclature and a newly proposed American Joint Committee on Cancer TNM staging, which complement each other. These neoplasms are of great medical and radiological interest because of their diverse presenting features and imaging appearances. There is an increased role for both anatomic and functional imaging in the assessment of these neoplasms. A review of the nomenclature, staging, and imaging is presented in this paper.

Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R (2009) Neuroendocrine tumors of the pancreas. The oncologist 14:456–467PubMedCrossRef

Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–S16PubMedCrossRef

Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135:1469–1492PubMedCrossRef

Yao JC, Hassan M, Phan A, et al. (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMedCrossRef

Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 36:933–942PubMedCrossRef

Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res 19:753–781CrossRef

Zerbi A, Falconi M, Rindi G, et al. (2010) Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 105(6):1421–1429PubMedCrossRef

Panzuto F, Nasoni S, Falconi M, et al. (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12:1083–1092PubMedCrossRef

Falconi M, Plockinger U, Kwekkeboom DJ, et al. (2006) Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196–211PubMedCrossRef

10.

Jensen RT, Berna MJ, Bingham DB, Norton JA (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113:1807–1843PubMedCrossRef

11.

Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22–32PubMedCrossRef

12.

Pape UF, Berndt U, Muller-Nordhorn J, et al. (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15:1083–1097PubMedCrossRef

13.

Kuzin NM, Egorov AV, Kondrashin SA, et al. (1998) Preoperative and intraoperative topographic diagnosis of insulinomas. World J Surg 22:593–597 ((discussion 597–598))PubMedCrossRef

14.

Sundin A, Vullierme MP, Kaltsas G, Plockinger U (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 90:167–183PubMedCrossRef

15.

D’Onofrio M, Mansueto G, Vasori S, Falconi M, Procacci C (2003) Contrast-enhanced ultrasonographic detection of small pancreatic insulinoma. J Ultrasound Med 22:413–417PubMed

16.

D’Onofrio M, Mansueto G, Falconi M, Procacci C (2004) Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging 29:246–258PubMedCrossRef

17.

Rockall AG, Reznek RH (2007) Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 21:43–68PubMedCrossRef

18.

De Angelis C, Carucci P, Repici A, Rizzetto M (1999) Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound 10:139–150PubMedCrossRef

19.

Chiti A, Fanti S, Savelli G, et al. (1998) Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 25:1396–1403PubMedCrossRef

20.

Gorman B, Charboneau JW, James EM, et al. (1986) Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR 147:929–934PubMedCrossRef

21.

Grover AC, Skarulis M, Alexander HR, et al. (2005) A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 138:1003–1008 ((discussion 1008))PubMedCrossRef

22.

Langer P, Kann PH, Fendrich V, et al. (2004) Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 28:1317–1322PubMedCrossRef

23.

Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM (2003) EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 58:531–535PubMedCrossRef

24.

Lonser RR, Glenn GM, Walther M, et al. (2003) von Hippel–Lindau disease. Lancet 361:2059–2067PubMedCrossRef

25.

Gouya H, Vignaux O, Augui J, et al. (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR 181:987–992PubMedCrossRef

26.

Rappeport ED, Hansen CP, Kjaer A, Knigge U (2006) Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 47:248–256PubMedCrossRef

27.

Boukhman MP, Karam JM, Shaver J, et al. (1999) Localization of insulinomas. Arch Surg 134:818–822 ((discussion 822–813))PubMedCrossRef

28.

Buetow PC, Parrino TV, Buck JL, et al. (1995) Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR 165:1175–1179PubMedCrossRef

29.

Rodallec M, Vilgrain V, Couvelard A, et al. (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85PubMedCrossRef

30.

Ahrendt SA, Komorowski RA, Demeure MJ, Wilson SD, Pitt HA (2002) Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg 6:66–74PubMedCrossRef

31.

Bordeianou L, Vagefi PA, Sahani D, et al. (2008) Cystic pancreatic endocrine neoplasms: a distinct tumor type? J Am Coll Surg 206:1154–1158PubMedCrossRef

32.

Bok EJ, Cho KJ, Williams DM, et al. (1984) Venous involvement in islet cell tumors of the pancreas. AJR 142:319–322PubMedCrossRef

33.

Shimizu K, Shiratori K, Toki F, et al. (1999) Nonfunctioning islet cell tumor with a unique pattern of tumor growth. Dig Dis Sci 44:547–551PubMedCrossRef

34.

Kitami CE, Shimizu T, Sato O, et al. (2000) Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg 7:529–533PubMedCrossRef

35.

Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB (2000) Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214:483–490PubMed

36.

Semelka RC, Custodio CM, Cem Balci N, Woosley JT (2000) Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 11:141–148PubMedCrossRef

37.

Dromain C, de Baere T, Baudin E, et al. (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR 180:121–128PubMedCrossRef

38.

Debray MP, Geoffroy O, Laissy JP, et al. (2001) Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 74:1065–1070PubMed

39.

Wang Y, Chen ZE, Yaghmai V, et al. (2011) Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 33:1071–1079PubMedCrossRef

40.

Tamm EP, Kim EE, Ng CS (2007) Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 21:409–432PubMedCrossRef

41.

Kwekkeboom DJ, Krenning EP (2002) Somatostatin receptor imaging. Semin Nuclear Medicine 32:84–91CrossRef

42.

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A (2010) ¹⁸F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16:978–985PubMedCrossRef

43.

Binderup T, Knigge U, Loft A, et al. (2010) Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and ¹⁸F-FDG PET. J Nucl Med 51:704–712PubMedCrossRef

44.

Eriksson B, Bergstrom M, Sundin A, et al. (2002) The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 970:159–169PubMedCrossRef

45.

Orlefors H, Sundin A, Garske U, et al. (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90:3392–3400PubMedCrossRef

46.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP (2011) Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Rel Cancer 18(Suppl 1):S27–S51CrossRef

47.

Kayani I, Bomanji JB, Groves A, et al. (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455PubMedCrossRef

48.

Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19:783–798PubMedCrossRef

49.

Fernandez-Cruz L, Saenz A, Astudillo E, et al. (2002) Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg 26:1057–1065PubMedCrossRef

50.

Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT (2006) Serum gastrin in Zollinger–Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine 85:295–330PubMedCrossRef

51.

Tomassetti P, Migliori M, Lalli S, et al. (2001) Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 12(Suppl 2):S95–S99PubMedCrossRef

52.

Weber HC, Venzon DJ, Lin JT, et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger–Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649PubMedCrossRef

53.

Skogseid B, Eriksson B, Lundqvist G, et al. (1991) Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73:281–287PubMedCrossRef

54.

Norton JA, Fraker DL, Alexander HR, et al. (1999) Surgery to cure the Zollinger–Ellison syndrome. New England J Med 341:635–644CrossRef

55.

Thompson NW, Vinik AI, Eckhauser FE (1989) Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger–Ellison syndrome. Annal Surg 209:396–404CrossRef

56.

Norton JA, Alexander HR, Fraker DL, et al. (2004) Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger–Ellison syndrome? Annal Surg 239:617–625 ((discussion 626))CrossRef

57.

Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT (1994) Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Annal Surg 220:320–328 ((discussion 328–330))CrossRef

58.

Cadiot G, Vuagnat A, Doukhan I, et al. (1999) Prognostic factors in patients with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger–Ellison (GRESZE). Gastroenterology 116:286–293PubMedCrossRef

59.

Norton JA, Fraker DL, Alexander HR, et al. (2006) Surgery increases survival in patients with gastrinoma. Annal Surg 244:410–419

60.

Ellison EC, Sparks J, Verducci JS, et al. (2006) 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg 202:897–905PubMedCrossRef

61.

Steinmuller T, Kianmanesh R, Falconi M, et al. (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62PubMedCrossRef

62.

O’Toole D, Ruszniewski P (2005) Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res 19:585–594CrossRef

63.

Kouvaraki MA, Ajani JA, Hoff P, et al. (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771PubMedCrossRef

64.

Nikou GC, Toubanakis C, Nikolaou P, et al. (2005) VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 52:1259–1265PubMed

65.

Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ (2008) Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg 12:382–393PubMedCrossRef

66.

Soga J, Yakuwa Y (1998) Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 17:389–400PubMed

67.

van Beek AP, de Haas ER, van Vloten WA, et al. (2004) The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 151:531–537PubMedCrossRef

68.

Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 75:53–63PubMedCrossRef

69.

Bartsch DK, Schilling T, Ramaswamy A, et al. (2000) Management of nonfunctioning islet cell carcinomas. World J Surg 24:1418–1424PubMedCrossRef

70.

Solorzano CC, Lee JE, Pisters PW, et al. (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085PubMedCrossRef

71.

Bloomston M, Muscarella P, Shah MH, et al. (2006) Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 10:1361–1370PubMedCrossRef

72.

Evans DB, Skibber JM, Lee JE, et al. (1993) Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114:1175–1181 ((discussion 1181–1172))PubMed

73.

Kulke MH, Stuart K, Earle C (2006) A phase II study of temozolomide and bevacizumab in patients with advance neuroendocrine tumors. J Clin Oncol 24(18S):4044

74.

Kulke MH, Blaszkowsky L, Zhu A (2010) Phase I/II study of everolimus (RAD001) in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors. Gastrointestinal Cancers Symposium 2010, Orlando, FL, p 223a

75.

Kulke MH, Stuart K, Enzinger PC, et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRef

76.

Schnirer II, Yao JC, Ajani JA (2003) Carcinoid—a comprehensive review. Acta oncologica (Stockholm, Sweden) 42:672–692CrossRef

77.

Rinke A, Muller HH, Schade-Brittinger C, et al. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663PubMedCrossRef

78.

Kulke MH, Lenz HJ, Meropol NJ, et al. (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410PubMedCrossRef

79.

Raymond E, Dahan L, Raoul JL, et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRef

80.

Phan AT, Yao JC, Fogelman D, et al. (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced lowgrade neuroendocrine carcinoma. J Clin Oncol 28:301sCrossRef

80.

Yao JC, Shah MH, Ito T, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedCrossRef

Titel: Pancreatic neuroendocrine neoplasms: diagnosis and management
verfasst von: Aparna Balachandran
Eric P. Tamm
Priya R. Bhosale
Madhavi Patnana
Raghu Vikram
Jason B. Fleming
Matthew H. Katz
Chuslip Charnsangavej
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Abdominal Radiology / Ausgabe 2/2013
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-012-9923-1

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pancreatic neuroendocrine neoplasms: diagnosis and management

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers

Routine use of precontrast and delayed acquisitions in abdominal CT: time for change

Lymphoepithelial cyst of the pancreas: comparison of CT findings with other pancreatic cystic lesions

Patterns of lymphatic drainage and lymph node involvement in esophageal cancer

Epithelioid angiomyolipoma of the liver: CT and MRI features

Lower gastrointestinal bleeding due to primary ilioenteric fistula

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie